Zuckerberg's Biohub leads a $1.8 billion push to build AI models that predict cell behavior. Biohub, the research organization backed by Mark Zuckerberg and Priscilla Chan, is coordinating a $1.8 billion initiative to train AI models that predict cell behavior. Meta, Google DeepMind, Isomorphic Labs, and the US Department of Energy are funding data, lab equipment, and compute. A first dataset should be ready in about a year. The article Zuckerberg's Biohub leads a $1.8 billion push to build AI models that predict cell behavior appeared first on The Decoder. What happened. The Chan Zuckerberg Biohub, the research organisation backed by Mark Zuckerberg and Priscilla Chan, is coordinating a $1.8 billion initiative to build AI models capable of predicting how cells behave. According to The Decoder, the effort draws on funding, data, laboratory equipment and compute from Meta, Google DeepMind, Isomorphic Labs and the US Department of Energy. The initiative is structured as a collaborative, multi-party programme rather than a single company's product push, bringing together commercial AI labs, a drug-discovery specialist in Isomorphic Labs, and a federal research agency. The first dataset produced under the programme is expected to be ready in roughly a year, which would then feed into model training aimed at simulating cellular behaviour. Why it matters. This is fundamentally a story about what AI can now be pointed at: not language or images, but the underlying biology that drives disease, drug response and treatment outcomes. If models can reliably predict how a cell will behave under given conditions, that capability could compress years of wet-lab experimentation into faster, cheaper computational cycles - reshaping how pharmaceutical and biotech organisations design and test interventions. For leaders tracking AI's trajectory, the significance lies in the coalition itself. Pairing frontier AI labs with a national research agency and a drug-discovery firm signals that large-scale, capital-intensive "foundation models for biology" are becoming a recognised category - one requiring the same infrastructure, data-pooling and compute commitments previously reserved for large language models. By the numbers. * $1.8 billion committed to the initiative coordinated by the Chan Zuckerberg Biohub. * Four named funding and resource partners: Meta, Google DeepMind, Isomorphic Labs and the US Department of Energy. * About one year is the expected timeline for the first dataset to be ready for model training. The renascence take. Coverage of this kind of announcement tends to focus on the funding figure and the marquee names involved. The more interesting signal is what it says about how AI capability is now being built: not as a single vendor's model release, but as shared infrastructure - pooled data, pooled compute, pooled lab resources - assembled specifically because no single organisation can generate biological ground-truth data at the scale a predictive model needs. For experience and transformation leaders outside biotech, the lesson isn't about cells - it's about data readiness. The most consequential AI capabilities rarely come from a better algorithm; they come from someone finally assembling the dataset nobody else had the patience or capital to build. Before asking what a model could predict for your organisation, ask the harder question: do Renascence actually have - or are Renascence willing to fund the multi-year work of creating - the ground-truth data that would make such a prediction trustworthy? Most organisations chasing AI outcomes skip straight past this step, and it's exactly where this initiative is choosing to start. This briefing was written by its Newsdesk, synthesising reporting from the outlets below. Follow the links for the original coverage. More in AI Stay ahead of CX Get the signal, not the noise. The stories shaping customer experience - plus the Journal and Experience Loom - in your inbox.

Funding the data behind AI biology. Language models learned from the text of the whole internet. Biology has no such library, and that shortage limits what AI can predict about cells and disease. To close the gap, Biohub, the US Department of Energy, the National Institutes of Health and several tech companies have committed $1.8 billion to build open biological data for AI, expanding an effort Biohub launched in April. Key takeaways. * The $1.8 billion package combines Biohub's $500 million, more than $500 million from the Department of Energy over five years, over $500 million in existing NIH-funded data, and $300 million from Google DeepMind, Isomorphic Labs and Meta. * Partners will record how cells respond to interventions across far more cell types and conditions, and build new tools to image and measure cells at scale. * All output is meant to be open, standardized and ready for training AI models, with a single point of access for researchers. Who brings what. Biohub, the research nonprofit backed by Mark Zuckerberg and Priscilla Chan, anchors the effort with its founding $500 million. It earmarked $400 million for new measurement and engineering technology and $100 million for research outside its own labs. The Department of Energy adds more than $500 million over five years through its Genesis Mission. That money covers lab measurement, modeling and computing. The agency also opens its heavy equipment: exascale supercomputers, autonomous laboratories, X-ray and neutron scattering, cryo-electron microscopy and tomography, the Joint Genome Institute and the Environmental Molecular Sciences Laboratory. The NIH contribution works differently. It brings no fresh cash. Instead, the agency will coordinate more than $500 million in past federal spending on existing datasets, repositories and knowledge bases, and help Biohub standardize them for AI training. Industry rounds out the total. Google DeepMind, Alphabet's drug-discovery arm Isomorphic Labs and Meta together pledged $300 million. Nvidia supplies computing infrastructure, software and expertise. The Allen Institute, Broad Institute, Gladstone Institutes, Human Cell Atlas, Human Protein Atlas and Wellcome Sanger Institute help organize the science, and Renaissance Philanthropy works to widen funding. What gets measured. The core product is response data: what happens to cells when researchers change them, across far more cell types and conditions than anyone has studied so far. The partners also plan multimodal datasets that combine different kinds of measurement in one place. New hardware and methods come with it. Biohub is developing cryo-electron tomography for atomic-level views inside cells, microscopy that can follow millions to billions of cells in living tissue, and tools to build and alter biology from single molecules up to whole organisms. Everything is supposed to flow into a shared, open resource with common standards and identifiers. The work builds on earlier Biohub projects, including Tabula Sapiens, OpenCell, Zebrahub, CELLxGENE and the CryoET Data Portal. The goal: A cell you can simulate. The partners want enough data to train a predictive model of a living cell, a tool that could test ideas in software before anyone touches a lab bench. Biohub head of science Alex Rives said such a model "could dramatically accelerate scientific discovery." Google DeepMind sees data as the bottleneck. "We will not solve this challenge without open, experimental biological data at an unprecedented scale," said Pushmeet Kohli, vice president of AI for science at Google DeepMind and chief scientist of Google Cloud. A crowded race to the virtual cell. Biohub is not alone in chasing this goal. In 2025, the Arc Institute launched a public competition to predict how cells respond when single genes are switched off, built on a fresh dataset of 300,000 human stem cells and backed by a top prize of $100,000. Contests like that showed both the promise and the problem: models improve fast, but only as fast as good experimental data arrives. Pooling money from government, philanthropy and tech companies attacks the second half of that equation. The federal role also fits a wider policy push. The Department of Energy runs the Genesis Mission as a national AI-for-science platform that links supercomputers, experimental facilities, AI systems and datasets across its national labs. Biology now joins energy and national security on that list. If the data stays open as promised, smaller labs and startups without big budgets could train useful models, instead of leaving AI biology to the few companies that can afford private data factories. You can offer your link to a page which is relevant to the topic of this post.

Biohub launches $1.8 billion AI biology initiative in major science push. The U.S. government, Google and Meta Platforms are joining forces with Biohub, the nonprofit founded by Mark Zuckerberg and Dr. Priscilla Chan, in a $1.8 billion initiative to develop large-scale biological datasets for artificial intelligence models, Reuters reported on Oct. 7. The initiative, known as the Virtual Biology Initiative, aims to generate data that can help AI systems predict how cells and biological systems respond to diseases, environmental conditions and potential treatments. The broader goal is to accelerate biomedical research and drug development by allowing scientists to conduct more experiments digitally. The funding includes $300 million from Meta, Google DeepMind and Isomorphic Labs. The U.S. Department of Energy is committing more than $500 million over five years. The National Institutes of Health is coordinating federal participation and contributing datasets, repositories, and other scientific resources backed by more than $500 million in previous federal investment. Biohub had earlier committed $500 million to the effort. The project is centered on creating what Biohub describes as a "virtual cell," a predictive model capable of simulating biological processes and helping researchers understand how cells react under different circumstances. Biohub said the initiative will use technologies including spatial transcriptomics and environmental response screening to generate large volumes of biological data. The resulting datasets are intended to become an open resource for researchers, although investors will receive an initial period of exclusive access to some data. Alex Rives, Biohub's head of science, said an accurate predictive model of biology could significantly accelerate scientific discovery by enabling researchers to conduct experiments digitally. Biohub expects to release its first major dataset within a year and aims to have functional predictive models within five years, according to Reuters. The initiative comes as technology companies and governments increasingly turn to AI for applications in drug discovery, disease research and clinical development. Other AI companies, including OpenAI and Anthropic, are also pursuing biological and pharmaceutical applications of AI. The Biohub effort represents a significant expansion of Zuckerberg and Chan's focus on biomedical science. Biohub was established in 2016 and has increasingly centered its work on using AI and large biological datasets to understand disease and develop new treatment approaches. The partnership also reflects a broader shift toward using AI to simulate biological processes rather than relying exclusively on physical laboratory experiments. AI companies are already developing tools that simulate potential drug responses and clinical trial outcomes, although human trials remain necessary to establish safety and effectiveness. For the U.S. government, the project also places federal scientific infrastructure behind the development of AI-ready biological data. NIH said its Bio Genesis Mission will bring together existing biomedical datasets, national data infrastructure and research programs to support predictive models of human biology. The initiative could eventually give researchers a way to test biological hypotheses at a scale that would be difficult, expensive or time-consuming to achieve through conventional experiments alone. Its success, however, will depend on the quality and breadth of the biological data used to train the models and on how accurately AI systems can reproduce complex human biology. Biohub and its partners are seeking to compress decades of biological research into a much shorter period, with the ultimate objective of improving scientists' ability to understand disease and identify potential treatments.